# US 2014/0275110 A1 · Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0275110 A1
- Document ID: US20140275110A1
- Status: Published application
- Kind: A1
- Application number: 14/251,384
- Filed: 2014-04-11
- Published: 2014-09-18
- Earliest claimed: 2007-12-07
- Assignees: AbbVie Deutschland GmbH & Co. KG
- Applicants: AbbVie Deutschland GmbH & Co. KG
- Inventors: Thorsten Oost; Astrid Netz; Hervé Geneste; Wilfried Braje; Wolfgang Wernet; Liliane Unger; Wilfried Hornberger; Wilfried Lubisch
- Web page: https://patentgrep.com/patent/US20140275110A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel amidomethyl-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.

## Claims

### Claim 1

A compound of the formula I
in which
R1 is hydrogen, methoxy or ethoxy;
R2 is hydrogen or methoxy;
R3 is hydrogen, methyl, ethyl, n-propyl or isopropyl;
X1 and X2 are N or CH, with the proviso that X1 and X2 are not simultaneously N;
and their pharmaceutically acceptable salts and prodrugs thereof.

### Claim 2 (depends on 1)

A compound as claimed in claim 1, in which R1 is hydrogen or methoxy.

### Claim 3

A compound as claimed in any of the preceding claims, in which R3 is hydrogen, methyl or ethyl.

### Claim 4

A compound as claimed in any of the preceding claims, in which X1 is N and X2 is CH.

### Claim 5 (depends on 1, 2, 3)

A compound as claimed in any of claims 1 to 3, in which X1 is CH and X2 is N.

### Claim 6

A compound as claimed in any of the preceding claims, in which
R1 is methoxy;
R2 is methoxy;
R3 is methyl;
X1 is CH; and
X2 is N.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A compound as claimed in any of claims 1 to 5, in which
R1 is methoxy;
R2 is methoxy;
R3 is methyl;
X1 is N; and
X2 is CH.

### Claim 8 (depends on 1, 2, 3, 4, 5)

A compound as claimed in any of claims 1 to 5, in which
R1 is methoxy;
R2 is methoxy;
R3 is methyl;
X1 is CH; and
X2 is CH.

### Claim 9 (depends on 1, 2, 3, 4, 5)

A compound as claimed in any of claims 1 to 5, in which
R1 is methoxy;
R2 is methoxy;
R3 is ethyl;
X1 is CH; and
X2 is N.

### Claim 10 (depends on 1, 2, 3, 4, 5)

A compound as claimed in any of claims 1 to 5, in which
R1 is methoxy;
R2 is methoxy;
R3 is ethyl;
X1 is N; and
X2 is CH.

### Claim 11

A compound as claimed in any of the preceding claims, which is the (−) enantiomer in an enantiomeric purity of at least 50% ee.

### Claim 12 (depends on 11)

A compound as claimed in claim 11, where the (−) enantiomer has an enantiomeric purity of at least 90% ee.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A compound as claimed in any of claims 1 to 10, which is the racemate.

### Claim 14

A pharmaceutical composition comprising at least one compound of the formula I as defined in any of the preceding claims and/or at least one pharmaceutically acceptable salt or prodrug thereof and at least one pharmaceutically acceptable carrier.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of vasopressin-dependent diseases.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from diabetes, insulin resistance, nocturnal enuresis, incontinence and diseases in which impairments of blood clotting occur, and/or for delaying micturition.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemias of the heart, impairments of the renal system, edemas, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, impairments of the gastrointestinal tract, gastritic vasospasm, hepatocirrhosis, gastric and intestinal ulcers, emesis, emesis occurring during chemotherapy, and travel sickness.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from affective disorders.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from anxiety disorders and stress-dependent anxiety disorders.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from memory impairments and Alzheimer's disease.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from psychoses and psychotic disorders.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from Cushing's syndrome and other stress-dependent diseases.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from sleep disorders.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from depressive disorders.

### Claim 25 (depends on 24)

The use as claimed in claim 24 for the treatment and/or prophylaxis of childhood onset mood disorders.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of vasomotor symptoms and/or thermoregulatory dysfunctions.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of drug or pharmaceutical dependencies and/or dependencies mediated by other factors; of stress caused by withdrawal of one or more factors mediating the dependence; and/or of stress-induced relapses into drug or pharmaceutical dependencies and/or dependencies mediated by other factors.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use of compounds of the formula I as defined in any of claims 1 to 13 or of pharmaceutically acceptable salts or prodrugs thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diseases selected from schizophrenia and psychosis.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for treating disorders defined as in any of claims 15 to 28, in which an effective amount of at least one compound of the formula I as defined in any of claims 1 to 13 or of at least one pharmaceutically acceptable salt or a prodrug thereof or of a pharmaceutical composition as claimed in claim 14 is administered to a patient.
